Diagnostic Kit
Zaoanxin Chronic Disease Screening Kit
Five Superiorities of World's First Kit Powered by Metabolomics-on-a-chip Technology
- Versatility: It's Can be used for both health indicator evaluation and disease risk prediction
- High efficiency: One tube of blood (30 μL)is enough for testing to generate eight reports
- Accuracy: It can Accurately predict early disease risk
- Safety: It's Noninvasive and safe
- Convenience: Tiny amount of blood is enough to evaluate health conditions of a person
One blood draw can be used for screening multiple chronic diseases
Health conditions can be assessed from multiple dimensions through the quantitative assay of four types of substances, namely, amino acids, bile acids, fatty acids, and neurotransmitters.
Relevant markers are used to identify the early risk of four diseases, namely, liver fibrosis and cirrhosis, diabetes, cardiovascular diseases, and gastrointestinal health.
Eight health reports can be generated based on one test
Early risk assessment of liver fibrosis and cirrhosis
Early risk assessment of diabetes
Early risk assessment of cardiovascular diseases
Gastrointestinal health assessment
Analysis of the balance of amino acid metabolism
Analysis of the balance of bile acid metabolism
Analysis of the balance of fatty acid metabolism
Neurotransmitter assay
Application Scenarios
Physical examination institutions, government-led health screening, clinical examination and online medical treatment
Patent No.
- Q300 Quantitative Test Kit Powered by Metabolomics-on-a-chip Technology (Patent No.: ZL201811223486.X, YSXB 20210363)
- Targeted Metabolome Batch Quantification (TMBQ) Software (Patent No.: CN201910170381.0)
- Integrated Platform for Mass Spectrometry-based Metabolomics Data Mining (IP4M) System (Patent No.: CN109061020A)
